May 1st 2024
The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Expert Highlights Importance of Biomarker Testing in Pancreatic Cancer
October 7th 2020At ISGIO 2020, Michael J. Pishvaian, MD, PhD, discussed the importance of using standard-of-care chemotherapy and to test for actionable mutations in patients with pancreatic cancers, which can identify ways to individualize therapy for these patients.
Read More
An Abundance of Targets Span the GI Malignancies Setting
October 6th 2020With the number of targets in gastrointestinal cancer growing, particularly KRAS in colorectal cancer and tumor mutational burden across all gastrointestinal tumors, Andrea Cercek, MD, sought to provide an overview of current and emerging targets during the 17th Annual Meeting of the International Society of Gastrointestinal Oncology.
Read More
Janjigian Reviews the Evolving Role of Anti-HER2 Agents in Advanced Gastric Cancer
October 5th 2020In an interview with Targeted Oncology following a virtual presentation for the ISGIO 2020, Yelena Janjigian, MD, provided an overview of the role of HER2-targeted therapies in advanced gastric cancer. She also explained the importance of biomarker testing in this space.
Read More
Germline Testing At Diagnosis Vital for Managing Pancreatic Cancers
October 5th 2020In an interview with Targeted Oncology following ISGIO 2020, Elena Chiorean, MD, oncologist, discussed universal genetic testing at the time of diagnosis for patients with pancreatic cancer, a topic she argued on during an ISGIO medical crossfire. She also explained the challenges with execute germline testing setting.
Read More
FDA Grants Fast Track Designation to DKN-01 in Gastric/GEJ Adenocarcinoma
September 24th 2020The FDA has granted a Fast Track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors express the protein DKK1, following disease progression on or after prior treatment with fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, human epidermal receptor growth factor/neu-targeted therapy.
Read More
Pembrolizumab Plus Chemotherapy Enters Frontline Treatment Landscape of Advanced Esophageal Cancer
September 21st 2020In the phase 3 KEYNOTE-590 clinical trial, frontline pembrolizumab plus chemotherapy demonstrated a significant improvement in overall survival, progression-free survival, and objective response rates versus chemotherapy only in patients with locally advanced unresectable or metastatic esophageal cancer, result presented during the 2020 ESMO Virtual Congress show.
Read More
Nivolumab Plus Chemotherapy Extends PFS With Durable Responses in Gastric/GEJ Cancers
September 21st 2020In the phase 3 ATTRACTION-4 study, nivolumab added to chemotherapy led to a statistically significant improvement in progression-free survival and induced higher overall response rates in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer, according to results presented during the 2020 ESMO Virtual Congress.
Read More
Significant PFS Benefit Observed With Surufatinib in Pancreatic NETs
September 21st 2020A statistically significant and clinically meaningful improvement in progression-free survival was observed with the use of surufatinib compared with placebo in patients with advanced pancreatic neuroendocrine tumors, meeting the primary end point of the randomized phase 3 SANET-p study.
Read More
Lanreotide Autogel Dosed More Frequently Delays More Toxic Regimens in Pancreatic, Midgut NETs
September 19th 2020For patients with progressive pancreatic or midgut neuroendocrine tumors, improvements in disease-free survival and progression-free survival were seen when the dosing of lanreotide Autogel was increased from 120 mg every 28 days to every 14 days. Data from the phase 2 CLARINET FORTE study suggest that this treatment option can delay switching to a more toxic treatment, which was presented at the 2020 ESMO Virtual Congress.
Read More
Promising Activity Seen With Dabrafenib Doublet in BRAF V600E+ Biliary Tract Cancer
September 18th 2020The combination of dabrafenib and trametinib in patients with biliary tract cancer and BRAF V600E mutations demonstrated clinical activity and a manageable safety profile, according to results from the phase 2 ROAR study.
Read More
Futibatinib Induces Durable Responses in FGFR2+ Intrahepatic Cholangiocarcinoma
September 18th 2020Futibatinib demonstrated efficacy and tolerability when administered as treatment of patients with intrahepatic cholangiocarcinoma who harbor FGFR2 fusions/rearrangements, according to interim analysis results presented in a poster during the the European Society of Medical Oncology Virtual Congress 2020
Read More
Doctors Debate: Should Perioperative Treatment of GEJ/Gastric Cancer Include Radiotherapy?
August 24th 2020During a debate at the 2020 Debates and Didactics in Hematology and Oncology Conference, Mehmet Akce, MD and Pretesh Patel, MD, argued their position on whether perioperative therapy for GEJ/gastric cancers should include radiation.
Read More
Promising Phase 3 Study of CPI-613 in Metastatic Pancreatic Cancer Achieves Target Enrollment Early
August 24th 2020In an interview with Targeted Oncology, Philip A. Philip, MD, PhD, discussed the current therapeutic options for patients with metastatic pancreatic cancer and where CPI-613 may fit into this treatment landscape.
Read More
Dabrafenib Plus Trametinib Phase 2 Data Inspire Hope for Targeted Therapy in Biliary Tract Cancer
August 19th 2020Vivek Subbiah, MD, discussed the positive findings from the phase 2 ROAR clinical trial, which evaluated the targeted therapy combination of dabrafenib and trametinib as treatment of patients with cholangiocarcinoma harboring a BRAF V600E mutation.
Read More
The primary end point of the phase 3 KEYNOTE-590 trial was met when the combination of pembrolizumab and chemotherapy improved overall survival (OS) and progression-free survival as initial treatment of patients with locally advanced or metastatic esophageal cancer during an interim analysis of the study.
Read More
Pembrolizumab Combo Extends Chemotherapy Benefit in Pancreatic Cancer
August 12th 2020Positive data from the phase IIa COMBAT clinical trial indicate that CXCR4 and PD-1 blockade with the combination of pembrolizumab and BL-8040 can improved upon the benefit of chemotherapy as treatment of pancreatic ductal adenocarcinoma.
Read More
Nivolumab/Ipilimumab Improves Survival Outcomes in Metastatic Gastric/GEJ Cancers
August 11th 2020Overall survival and progression-free survival were improved with nivolumab plus ipilimumab and chemotherapy compared with chemotherapy alone as frontline treatment of patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
Read More
Promising Data Follow on First Targeted Therapy Approval in Biliary Tract Cancer
July 27th 2020Like never before, presentations related to systemic therapies for biliary tract cancers are taking center stage at medical and oncology conferences, generating hope that treating physicians will have multiple options in the near future.
Read More
In an interview with Targeted Oncology, Bassel El-Rayes, MD, discussed the treatment options for patients with borderline resectable pancreatic cancer. He also discussed sequencing the available agents for borderline resectable pancreatic cancer and the role of circulating tumor DNA in guiding individualized treatment of the disease.
Read More